REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 1,846,275	$ 1,860,455	$ 1,704,048
Product
Disaggregation of Revenue [Line Items]
Revenue	1,783,498	1,805,861	1,661,043
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse
Disaggregation of Revenue [Line Items]
Revenue	1,660,733	1,675,754	1,563,234
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | United States
Disaggregation of Revenue [Line Items]
Revenue	657,700	756,863	669,171
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Europe
Disaggregation of Revenue [Line Items]
Revenue	558,952	498,725	485,596
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Latin America
Disaggregation of Revenue [Line Items]
Revenue	191,151	205,862	218,792
Marketed by Company | Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse | Rest of world
Disaggregation of Revenue [Line Items]
Revenue	252,930	214,304	189,675
Marketed by Sanofi | Aldurazyme
Disaggregation of Revenue [Line Items]
Revenue	$ 122,765	$ 130,107	$ 97,809